| Title |
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
|
|---|---|
| Published in |
CNS Drugs, June 2017
|
| DOI | 10.1007/s40263-017-0444-x |
| Pubmed ID | |
| Authors |
Peter Joseph Jongen |
| Abstract |
Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and magnetic resonance imaging abnormalities. This article reviews published data from randomized controlled trials and observational studies regarding the effects of currently available DMDs on HRQoL. Data indicate that DMD treatment is associated with prevention of worsening or with improvement of HRQoL, and that, in general, second-line DMDs may have a greater impact on HRQoL than first-line DMDs. In clinical practice, monitoring of HRQoL provides clinicians with unique information regarding disease impact and potential benefits and adverse effects of DMD treatment that may not be obtained otherwise; it might also permit early detection of an unfavorable disease course. It is suggested to assess HRQoL at the time of diagnosis and before starting or switching DMD treatment. Regular HRQoL measurements contribute to a comprehensive clinical evaluation, and may help to elucidate and quantify the patient's contribution to shared decision making regarding DMD treatment. Further studies are needed to better determine the role of HRQoL assessments in daily MS care. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 105 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 14% |
| Student > Bachelor | 14 | 13% |
| Researcher | 13 | 12% |
| Student > Ph. D. Student | 13 | 12% |
| Student > Doctoral Student | 6 | 6% |
| Other | 13 | 12% |
| Unknown | 31 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 23% |
| Neuroscience | 9 | 9% |
| Psychology | 9 | 9% |
| Nursing and Health Professions | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Other | 17 | 16% |
| Unknown | 34 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2021.
All research outputs
#2,967,691
of 22,981,247 outputs
Outputs from CNS Drugs
#259
of 1,314 outputs
Outputs of similar age
#57,043
of 317,411 outputs
Outputs of similar age from CNS Drugs
#5
of 20 outputs
Altmetric has tracked 22,981,247 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,411 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.